TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.9688
+0.1288 (15.33%)
At close: Jun 26, 2026, 4:00 PM EDT
0.8851
-0.0837 (-8.64%)
After-hours: Jun 26, 2026, 6:54 PM EDT
TScan Therapeutics Revenue
TScan Therapeutics had revenue of $982.00K in the quarter ending March 31, 2026, a decrease of -54.77%. This brings the company's revenue in the last twelve months to $9.14M, up 106.65% year-over-year. In the year 2025, TScan Therapeutics had annual revenue of $10.33M with 266.65% growth.
Revenue (ttm)
$9.14M
Revenue Growth
+106.65%
P/S Ratio
6.93
Revenue / Employee
$65,727
Employees
139
Market Cap
63.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.33M | 7.51M | 266.65% |
| Dec 31, 2024 | 2.82M | -18.23M | -86.62% |
| Dec 31, 2023 | 21.05M | 7.51M | 55.52% |
| Dec 31, 2022 | 13.54M | 3.39M | 33.47% |
| Dec 31, 2021 | 10.14M | 9.06M | 834.65% |
| Dec 31, 2020 | 1.09M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTCRX News
- 3 days ago - TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 5 days ago - TScan Therapeutics Transcript: KOL event - Transcripts
- 5 days ago - TScan Therapeutics Press release: KOL event - Filings
- 5 days ago - TScan Therapeutics Slides: KOL event - Filings
- 5 days ago - TScan Therapeutics presents data from Cohort C of ALLOHA trial - TheFly
- 5 days ago - TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - GlobeNewsWire
- 24 days ago - TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing - TheFly
- 24 days ago - Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Business Wire